When to add anti-angiogenesis drugs to EGFR-mutated metastatic non–small cell lung cancer patients: a real-world study from Taiwan

Overview of attention for article published in BMC Cancer, May 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 5 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 940 followers.

When to add anti-angiogenesis drugs to EGFR-mutated metastatic non-small cell lung cancer patients: a real-world study from Taiwan https://t.co/8mDdjdB9i4

23 May 2022

Reply Repost Favourite

New article: When to add anti-angiogenesis drugs to EGFR-mutated metastatic non-small cell lung cancer patients: a real-world study from Taiwan https://t.co/1F8UGjLrax #lungcancer #oncology https://t.co/zMgJebESIp

23 May 2022

Reply Repost Favourite

New article: When to add anti-angiogenesis drugs to EGFR-mutated metastatic non-small cell lung cancer patients: a real-world study from Taiwan https://t.co/vSCF08dAnn #livercancer #oncology https://t.co/LmijaDsn6N

23 May 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.